Lifestyle Affects Amyloid Burden and Cognition Differently in Men and Women
Overview
Authors
Affiliations
Objective: Evidence on associations of lifestyle factors with Alzheimer's pathology and cognition are ambiguous, potentially because they rarely addressed inter-relationships of factors and sex effects. While considering these aspects, we examined the relationships of lifestyle factors with brain amyloid burden and cognition.
Methods: We studied 178 cognitively normal individuals (women, 49%; 65.0 [7.6] years) and 54 individuals with mild cognitive impairment (women, 35%; 71.3 [8.3] years) enrolled in a prospective study of volunteers who completed F-Flutemetamol amyloid positron emission tomography. Using structural equation modeling, we examined associations between latent constructs representing metabolic/vascular risk, physical activity, and cognitive activity with global amyloid burden and cognitive performance. Furthermore, we investigated the influence of sex in this model.
Results: Overall, higher cognitive activity was associated with better cognitive performance and higher physical activity was associated with lower amyloid burden. The latter association was weakened to a nonsignificant level after excluding multivariate outliers. Examination of the moderating effect of sex in the model revealed an inverse association of metabolic/vascular risk with cognition in men, whereas in women metabolic/vascular risk trended toward increased amyloid burden. Furthermore, a significant inverse association between physical activity and amyloid burden was found only in men. Inheritance of an APOE4 allele was associated with higher amyloid burden only in women.
Interpretation: Sex modifies effects of certain lifestyle-related factors on amyloid burden and cognition. Notably, our results suggest that the negative impact of metabolic/vascular risk influences the risk of cognitive decline and Alzheimer's disease through distinct paths in women and men. ANN NEUROL 2022;92:451-463.
Moderation of midlife cognitive activity on tau-related cognitive impairment.
Ko K, Yi D, Byun M, Jung J, Kong N, Jung G Alzheimers Dement. 2025; 21(2):e14606.
PMID: 39988958 PMC: 11847999. DOI: 10.1002/alz.14606.
Cacciaglia R, Falcon C, Benavides G, Brugulat-Serrat A, Aloma M, Calvet M Alzheimers Dement. 2025; 21(2):e14415.
PMID: 39898436 PMC: 11848178. DOI: 10.1002/alz.14415.
Hypertension and cerebral blood flow in the development of Alzheimer's disease.
Bachmann D, Saake A, Studer S, Buchmann A, Rauen K, Gruber E Alzheimers Dement. 2024; 20(11):7729-7744.
PMID: 39254220 PMC: 11567827. DOI: 10.1002/alz.14233.
Soldevila-Domenech N, Fagundo B, Cuenca-Royo A, Forcano L, Gomis-Gonzalez M, Boronat A Nutr J. 2024; 23(1):61.
PMID: 38862960 PMC: 11167771. DOI: 10.1186/s12937-024-00966-w.
Xie J, You Y, Zheng P, Chen Y, Guo S, Xu Y BMJ Open. 2024; 14(5):e080789.
PMID: 38806426 PMC: 11138272. DOI: 10.1136/bmjopen-2023-080789.